The Human Brain Project, co-funded by the European Union, plans to use supercomputers to model the brain and then simulate drugs and treatments for diseases that cost hundreds of billions of euros annually in Europe alone.
Unfortunately, because innovative ideas are ones no one else has, we can’t know for certain how successful those ideas will be. Likewise, because they are new and different, the development expense of innovative ideas is often high. The bottom line is that the risk of new and different ideas is great.
What sounds like a dream of the future has already been the subject of research for a few years: simply printing out tissue and organs. Now scientists have further refined the technology and are able to produce various tissue types.
Making best use of resources is good, but figuring out how isn’t necessarily a Lean Event. Five-S is a good practice, but declaring an emergency just to clean up appearances for a visitor completely misses the intent. Quotas of activity do not necessarily beget improved performance.
The Missouri Society of Anesthesiologists statement followed an Associated Press report last week citing possible European export controls if propofol is used in a U.S. execution. Missouri is the only U.S. state where prison officials plan to use the powerful anesthetic for a lethal injection, citing a shortage in the drugs usually used for executions.
On the brink of a government shutdown, the Senate voted 54-46 on Monday to strip a one-year delay in President Barack Obama's health care law from the bill that would keep the government operating. The Senate also stripped a provision that would have eliminated the tax on medical devices.
More than 235 million people worldwide suffer from asthma, according to the World Health Organization. So, when Italian pharmaceutical company, ChiesiFarmaceutici, developed a new medicine in the form of a powder, they turned to product development firm Cambridge Consultants for a revolutionary inhaler design.
Medical device maker Integra LifeSciences said Thursday that it has resolved a mold problem at a collagen manufacturing facility in Plainsboro, N.J.In December 2011, the Food and Drug Administration sent Integra a warning letter about mold in the facility, saying it could affect the company's products.
This year's study, based on respondents in the United States, China, India, Germany and Brazil, highlighted some of the characteristics of a more complex global marketplace. It found that while fundamentals such as quality, safety and innovation remain the most important factors driving behavior for manufacturers and consumers, a number of priorities such as transparency, health impact and outsourcing/country of origin are on the rise.
Tommy and Barbara Sowards are suing for damages after they say the doctor implanted an unneeded pacemaker when Tommy Sowards went to MountainView Regional Medical Center in Las Cruces in January 2007. They're suing cardiologist Dr. Demosthenes Klonis, the hospital and pacemaker manufacturer Biotronik, Inc.
Stryker is buying Mako Surgical for about $1.41 billion, giving the medical device maker access to all of its robotic assisted surgery technology. Stryker will pay $30 per Mako share, an 86 percent premium to its $16.17 closing price Tuesday. The companies put the deal's value at about $1.65 billion.
IDSA is my favorite conference to attend because it’s not just people talking about good design; it’s filled with conversations about how design can transform lives. It’s a very powerful message, especially in today’s society of design-centric businesses.
The Food and Drug Administration published new rules Friday that require certain medical devices sold in the U.S. to carry a unique code, identifying its make, manufacturer and lot number. The codes will be stored in a publicly accessible database to help regulators, doctors and companies monitor safety issues with devices.
We are constantly bombarded by the “fact” that we are overspending on social programs, which jeopardizes the wonderful future that our great grandchildren so richly deserve. Let’s get this straight, no one deserves anything. Every generation must earn its place.
Laser and optics manufacturer II-VI Inc. has acquired the semiconductor laser business of Oclaro Inc. for $92 million. Oclaro's shares jumped 30 percent to $1.38 before the opening bell Thursday. II-VI is acquiring semiconductor laser technology used in laser system products for material processing, medical, consumer and fiber optic communications.
The device looks like a robot's hand in a science fiction movie, costs about $500 to make and can be reproduced using plans on the Internet and a 3D printer.Van As is now on a mission to spread the mechanism to people without fingers or hands all over the world.
The philanthropists Bill and Melinda Gates, as well as five researchers, have won prestigious Lasker Awards for their contributions to medicine. The Albert and Mary Lasker Foundation announced the recipients of the $250,000 prizes on Monday. The Gateses were honored for their work on health problems around the world.
For the first time, certain vaccines will guard against four strains of flu rather than the usual three. Called quadrivalent vaccines, these brands may prove more popular for children than their parents. That's because kids tend to catch the newly added strain more often.
Johnson & Johnson says the warning will appear on the cap of each new bottle of Extra Strength Tylenol sold in the U.S. in October and on most other Tylenol bottles in coming months. The warning will make it explicitly clear that the over-the-counter drug contains acetaminophen, a pain-relieving ingredient that's the nation's leading cause of sudden liver failure.
UH researcher Jose Luis Contreras-Vidal, professor of electrical and computer engineering, is working on perfecting a non-invasive brain-machine interface (BMI) technology that a patient can use to operate an advanced robotics system such as the exoskeleton. The BMI works by interpreting brain waves that allow patients to control, with their thoughts, robotic legs and below-elbow amputees to control neuroprosthetic limbs.
Pharmacyclics is getting a priority review of its blood cancer treatment by federal regulators. A priority review shortens a drug evaluation by the Food and Drug Administration from 10 months to six. The acceptance of the application triggers a $75 million milestone payment to Pharmacyclics from Johnson & Johnson's Janssen unit.
Endo Health Solutions said Wednesday it will buy Boca Pharmacal for $225 million in a deal that expands its generic drug business. Boca Pharmacal says it makes "niche" generic drugs. Endo said privately-held Boca focuses on products that require special handling or administration.
Akorn Inc. plans to pay $640 million in cash to buy fellow generic drugmaker Hi-Tech Pharmacal Co. Inc. in a deal that it expects will help boost its adjusted earnings immediately. Lake Forest, Ill.-based Akorn said that it will pay $43.50 for each share of Amityville, N.Y.-based Hi-Tech. That represents a premium of more than 23 percent over Hi-Tech's closing price Monday of $35.21.
California pharmacists would be allowed to dispense substitute medications that are biologically similar to brand-name treatments under a bill that cleared the state Assembly on Monday. Biological medicines, which are created from living cells rather than by mixing chemicals, have been used to treat cancer and immune-system disorders.
Biotech drugmaker Amgen will buy cancer drug maker Onyx Pharmaceuticals for about $10.4 billion in cash in a deal that will add several cancer drugs to Amgen's stable and add to its pipeline of new drugs. Amgen Inc. said Sunday it will acquire Onyx for $125 per share, and it expects to complete the deal at the beginning of the fourth quarter.